

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

· 1.1 Product identifier

· Trade name: human Opioid mu AequoZen®

· Product number: ES-542-AF

· 1.2 Relevant identified uses of the substance or mixture and uses advised against

No further relevant information available.

· Product category PC21 Laboratory chemicals

· Application of the substance / the mixture Laboratory chemicals

· 1.3 Details of the supplier of the safety data sheet

· Manufacturer/Supplier:

Revvity, Inc 549 Albany Street Boston, MA 02118

· Further information obtainable from:

US Technical Support 800-762-4000

· 1.4 Emergency telephone number:

If inside USA, call CHEMTREC at 1-800-424-9300 If outside USA, call CHEMTREC at 1-703-527-3887

### SECTION 2: Hazards identification

- · 2.1 Classification of the substance or mixture
- · 2.1.1 Classification according to Regulation (EC) No 1272/2008

Skin Irrit. 2 H315 Causes skin irritation.

Eye Irrit. 2 H319 Causes serious eye irritation.

- 2.1.3 Additional information: For the wording of the relevant risk phrases refer to section 16.
- · 2.2 Label elements
- · Labelling according to Regulation (EC) No 1272/2008

The product is classified and labelled according to the CLP regulation.

· Hazard pictograms



- · Signal word Warning
- · Hazard statements

H315 Causes skin irritation.

H319 Causes serious eye irritation.

· Precautionary statements

P264 Wash thoroughly after handling. P280 Wear eye protection / face protection.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if

present and easy to do. Continue rinsing.

P332+P313 If skin irritation occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before reuse.
P337+P313 If eye irritation persists: Get medical advice/attention.

- · 2.3 Other hazards
- · Results of PBT and vPvB assessment
- · **PBT:** Not applicable.

(Contd. on page 2)

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

· vPvB: Not applicable.

(Contd. of page 1)

#### SECTION 3: Composition/information on ingredients

- . 3 2 Mixtures
- · Description: Mixture of substances listed below with nonhazardous additions.

· Dangerous compone
---------------------

CAS: 67-68-5 dimethyl sulfoxide EINECS: 200-664-3

🕟 Skin Irrit. 2, H315; Eye Irrit. 2, H319

2.5-10%

Additional information: For the wording of the relevant risk phrases refer to section 16.

### SECTION 4: First aid measures

- · 4.1 Description of first aid measures
- · General information: Immediately remove any clothing soiled by the product.
- · After inhalation: In case of unconsciousness place patient stably in side position for transportation.
- · After eye contact:

Rinse opened eye for several minutes under running water. If symptoms persist, consult a doctor.

- · After swallowing: If symptoms persist consult doctor.
- 4.2 Most important symptoms and effects, both acute and delayed No further relevant information available.
- · 4.3 Indication of any immediate medical attention and special treatment needed No further relevant information available.

### **SECTION 5: Firefighting measures**

- 5.1 Extinguishing media
- · Suitable extinguishing agents:

CO2, powder or water spray. Fight larger fires with water spray or alcohol resistant foam.

- 5.2 Special hazards arising from the substance or mixture No further relevant information available.
- · 5.3 Advice for firefighters
- · Protective equipment: Wear self-contained respiratory protective device.

### SECTION 6: Accidental release measures

- · 6.1 Personal precautions, protective equipment and emergency procedures Not required.
- 6.2 Environmental precautions: Do not allow to enter sewers/surface or ground water.
- 6.3 Methods and material for containment and cleaning up: Pick up mechanically.
- · 6.4 Reference to other sections

See Section 7 for information on safe handling.

See Section 8 for information on personal protection equipment.

See Section 13 for disposal information.

#### SECTION 7: Handling and storage

· 7.1 Precautions for safe handling

Store in cool, dry place in tightly closed receptacles.

No special precautions are necessary if used correctly.

· Information about fire - and explosion protection: No special measures required.

(Contd. on page 3)

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

(Contd. of page 2)

- 7.2 Conditions for safe storage, including any incompatibilities
- · Storage:
- Requirements to be met by storerooms and containers: No special requirements.
- · Information about storage in one common storage facility: Not required.
- · Further information about storage conditions: Keep container tightly sealed.
- · Storage class: 11
- · 7.3 Specific end use(s) No further relevant information available.

### SECTION 8: Exposure controls/personal protection

- · 8.1 Control parameters
- · Ingredients with limit values that require monitoring at the workplace:

The product does not contain any relevant quantities of materials with critical values that have to be monitored at the workplace.

- · Additional information: The lists valid during the making were used as basis.
- · 8.2 Exposure controls
- · Appropriate engineering controls No further data; see section 7.
- · Individual protection measures, such as personal protective equipment
- · General protective and hygienic measures:

Keep away from foodstuffs, beverages and feed.

Immediately remove all soiled and contaminated clothing

Wash hands before breaks and at the end of work.

Avoid contact with the eyes and skin.

- · Respiratory protection: Suitable respiratory protective device recommended.
- · Hand protection



Protective gloves

The glove material has to be impermeable and resistant to the product/ the substance/ the preparation.

Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

· Material of gloves

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

· Penetration time of glove material

The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

· Eye/face protection



Tightly sealed goggles

### SECTION 9: Physical and chemical properties

- · 9.1 Information on basic physical and chemical properties
- · General Information
- · Physical state Solid

(Contd. on page 4)

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

(Contd. of page 3) · Colour: According to product specification · Odour: Characteristic · Odour threshold: Not determined. · Melting point/freezing point: Undetermined. · Boiling point or initial boiling point and boiling range 189 °C · Flammability Not determined. · Lower and upper explosion limit · Lower: 1.8 Vol % · Upper: 63 Vol % · Flash point: 95 °C · Auto-ignition temperature: 270 °C Not determined. · Decomposition temperature: Not applicable.  $\cdot pH$ · Viscosity: · Kinematic viscosity Not applicable. · Dynamic: Not applicable. ·Solubility Insoluble. · water: · Partition coefficient n-octanol/water (log value) Not determined. · Vapour pressure at 20 °C: 2.5 hPa Density and/or relative density · Density: Not determined. · Relative density Not determined. · Vapour density Not applicable. · Particle characteristics See section 3. · 9.2 Other information · Appearance: · Form: Solid · Important information on protection of health and environment, and on safety. · Ignition temperature: Product is not selfigniting. · Explosive properties: Product does not present an explosion hazard. · Solvent content: · Organic solvents: 10.0% · Change in condition · Evaporation rate Not applicable. · Information with regard to physical hazard classes · Explosives Void · Flammable gases Void Void · Aerosols · Oxidising gases Void · Gases under pressure Void · Flammable liquids Void · Flammable solids Void · Self-reactive substances and mixtures Void · Pyrophoric liquids Void · Pyrophoric solids Void · Self-heating substances and mixtures Void · Substances and mixtures, which emit flammable gases Void in contact with water Oxidising liquids Void

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

(Contd. of page 4)

· Oxidising solids	Void
· Organic peroxides	Void
· Corrosive to metals	Void
· Desensitised explosives	Void

### SECTION 10: Stability and reactivity

- · 10.1 Reactivity No further relevant information available.
- · 10.2 Chemical stability
- Thermal decomposition / conditions to be avoided: No decomposition if used according to specifications.
- · 10.3 Possibility of hazardous reactions No dangerous reactions known.
- · 10.4 Conditions to avoid No further relevant information available.
- · 10.5 Incompatible materials: No further relevant information available.
- · 10.6 Hazardous decomposition products: No dangerous decomposition products known.

### SECTION 11: Toxicological information

- · 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
- · Acute toxicity Based on available data, the classification criteria are not met.
- · Skin corrosion/irritation Causes skin irritation.
- · Serious eve damage/irritation Causes serious eye irritation.
- · Respiratory or skin sensitisation Based on available data, the classification criteria are not met.
- · Germ cell mutagenicity Based on available data, the classification criteria are not met.
- · Carcinogenicity Based on available data, the classification criteria are not met.
- Reproductive toxicity Based on available data, the classification criteria are not met.
- · STOT-single exposure Based on available data, the classification criteria are not met.
- · STOT-repeated exposure Based on available data, the classification criteria are not met.
- · Aspiration hazard Based on available data, the classification criteria are not met.
- · 11.2 Information on other hazards
- Endocrine disrupting properties

None of the ingredients is listed.

### SECTION 12: Ecological information

- · 12.1 Toxicity
- · Aquatic toxicity: No further relevant information available.
- · 12.2 Persistence and degradability No further relevant information available.
- · 12.3 Bioaccumulative potential No further relevant information available.
- · 12.4 Mobility in soil No further relevant information available.
- · 12.5 Results of PBT and vPvB assessment
- · **PBT:** Not applicable.
- · vPvB: Not applicable.
- · 12.6 Endocrine disrupting properties

*The product does not contain substances with endocrine disrupting properties.* 

· 12.7 Other adverse effects No further relevant information available.

• EU

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

(Contd. of page 5)

### SECTION 13: Disposal considerations

- · 13.1 Waste treatment methods
- · Recommendation

Must not be disposed together with household garbage. Do not allow product to reach sewage system. Hand over to hazardous waste disposers.

Must be specially treated adhering to official regulations.

- · Uncleaned packaging:
- · Recommendation: Disposal must be made according to official regulations.

Void
Void
Void
No
Not applicable.
)

### SECTION 15: Regulatory information

- · 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
- · Directive 2012/18/EU
- · Named dangerous substances ANNEX I None of the ingredients is listed.
- DIRECTIVE 2011/65/EU on the restriction of the use of certain hazardous substances in electrical and electronic equipment Annex II

None of the ingredients is listed.

- · REGULATION (EU) 2019/1148
- · Annex I RESTRICTED EXPLOSIVES PRECURSORS (Upper limit value for the purpose of licensing under Article 5(3))

None of the ingredients is listed.

#### · Annex II - REPORTABLE EXPLOSIVES PRECURSORS

None of the ingredients is listed.

(Contd. on page 7)

Printing date 13.02.2024 Version number 1 Revision: 15.08.2023

Trade name: human Opioid mu AequoZen®

(Contd. of page 6)

· Regulation (EC) No 273/2004 on drug precursors

None of the ingredients is listed.

Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors

None of the ingredients is listed.

· 15.2 Chemical safety assessment: A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

The information provided in this safety data sheet is based on our current knowledge, and is believed to be correct at the date of publication. However, no representation is made concerning its accuracy and completeness. It is intended as guidance only, and is not to be regarded as a warranty or specification of quality. All materials may present unknown hazards and should be used with caution. Although certain hazards are described, we cannot guarantee that these are the only hazards that exist. Revvity, Inc. cannot be held liable for any damage resulting from handling or contact with the product.

#### · Abbreviations and acronyms:

ADR: Accord relatif au transport international des marchandises dangereuses par route (European Agreement Concerning the International Carriage of Dangerous Goods by Road)

IMDG: International Maritime Code for Dangerous Goods

IATA: International Air Transport Association

GHS: Globally Harmonised System of Classification and Labelling of Chemicals

EINECS: European Inventory of Existing Commercial Chemical Substances

ELINCS: European List of Notified Chemical Substances

CAS: Chemical Abstracts Service (division of the American Chemical Society)

PBT: Persistent, Bioaccumulative and Toxic

vPvB: very Persistent and very Bioaccumulative

Skin Irrit. 2: Skin corrosion/irritation – Category 2

Eye Irrit. 2: Serious eye damage/eye irritation – Category 2

- FII